Clinical trials: Vancomycin Resistant Enterococci Infection
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Infection Due to Resistant Organism
FMT for MDRO Colonization After Infection in Renal Transplant Recipients
Transplant patients are at increased risk of colonization and infection with Multidrug Resistant Organisms (MDROs) due to medications that modify their immune systems, increased healthcare and antibiotic exposure, and surgical…
- Trial name
- PREMIX (NCT02922816)
- Testing
- Fecal Microbiota Transplant (FMT), Bowel preparation, Stool or perirectal swab sampling
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA)
A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization
Multidrug-resistant organisms (MDROs) cause serious infections that are difficult to treat, leading to increased morbidity and mortality, longer hospital stays, and increased healthcare costs.
- Conditions
- Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci, Carbapenem-Resistant Enterobacteriaceae
- Trial name
- MDRO-Fiber (NCT07792915)
- Testing
- Resistant Potato Starch, Maltodextrin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- VA Office of Research and Development
Bacterial Infections
New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
- Trial name
- NCT00035854
- Testing
- Zyvox® / Linezolid
- Where
- 21 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
VRE Infection, Antibiotic Resistant Infection
Assessing the Impact of Antimicrobial Exposure and Infection Control Measures on the Spread of VRE
The AEGON study is a German multicenter, prospective observational study. The study consists of two parts, which are carried out at all participating study sites and include two different patient cohorts.
- Trial name
- AEGON (NCT04624464)
- Testing
- Rectal swabs - microbiological analysis, Examination of patient room
- Where
- Germany
- Volunteers
- 170 people
- Sponsor
- University Hospital of Cologne
Multidrug Resistant Organisms, Healthcare Associated Infections
Effectiveness of Enhanced Terminal Room Disinfection to Prevent Healthcare-associated Infections (HAIs)
Enhanced terminal room disinfection is a novel, promising, but still unproven strategy for the prevention of healthcare-associated infections (HAIs) due to selected multidrug-resistant (MDR) bacterial pathogens.
- Trial name
- NCT01579370
- Testing
- Quaternary ammonium, Bleach, Quaternary ammonium and UV-C light
- Where
- 9 sites in United States
- Volunteers
- 21,395 people
- Sponsor
- Duke University
Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
The goal of this clinical trial is to determine if oral vancomycin can prevent C.diff infection in adults who are critically ill and are at high risk of C.diff infection due to their medical conditions and being in the hospital.
- Trial name
- NCT07221370
- Testing
- Vancomycin 125mg
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- Riverside University Health System Medical Center
Patients at High Risk of Antibacterial Treatment Upon Admission
Impact of Prescription Quality, Infection Control and Antimicrobial Stewardship on Gut Microbiota Domination by Healthcare-Associated Pathogens
Extended-spectrum beta-lactamase producing Enterobacteriaceae (EPE), vancomycin-resistant enterococci (VRE) and Clostridium difficile have become a major threat to hospitalised patients worldwide.
- Trial name
- PILGRIM (NCT03765528)
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- University Hospital of Cologne
Gram-Positive Bacterial Infections
Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit
To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit…
- Trial name
- NCT00167960
- Testing
- Piperacillin/tazobactam and other β-lactam/β-lactamase
- Where
- 2 sites in South Korea
- Volunteers
- 1,500 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Anti-biotic Resistance
A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE
The purpose of this study is to investigate the feasibility, safety and efficacy of oral probiotic, VSL#3 versus oral placebo for reducing colonization by VRE.
- Trial name
- PROVE (NCT00933556)
- Testing
- VSL#3
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Wisconsin, Madison
MRSA, VRE Infection
Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE
Hospital-acquired infections are common and frequently lead to poor outcomes, including death, in affected patients. Two common organisms that cause infections in the hospital are methicillin-resistant Staphylococcus aureus…
- Trial name
- CONTACT-PILOT (NCT03268122)
- Testing
- Standard Contact Isolation, Targeted Contact Isolation
- Where
- United States
- Volunteers
- 1,974 people
- Sponsor
- Vanderbilt University Medical Center
Escherichia Coli Infections, Klebsiella Infections
Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care
To determine whether the restriction of 3rd generation cephalosporins and carbapenems contribute to the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a medical intensive care…
- Trial name
- NCT00167986
- Testing
- vancomycin-resistant enterococci and ESBL
- Where
- South Korea
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Intestinal Multi-drug Resistant Organism Colonization
Further MT for Antibiotic-Resistant Bacterial Colonization
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection.
- Trial name
- FAIR (NCT05835206)
- Testing
- Microbiome Therapeutic
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Infection
Reduction of Nosocomial Vancomycin -Resistant Enterococci (VRE) Colonization and Infection by Active Surveillance and Intervention of Infection Control
Vancomycin -resistant enterococci(VRE) has emerged as one of the most common nosocomial pathogen of health-care associated infection since 1988.
- Trial name
- NCT01201031
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Medical University WanFang Hospital
Infection
The Epidemiology of Infection With Vancomycin-Resistant Enterococci
Current projects study veteran patients with chronic ulcers and MRSA colonization and infection, patients with imipenem-resistant P.
- Trial name
- NCT00018434
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Clostridium Difficile Infection, VRE Infection
Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium Difficile, Vancomycin-Resistant Enterococci or Multi-Resistant Gram-Negatives
Throughout project, the investigators design, evaluate and disseminate infection control and antibiotic stewardship (ABS) measures aimed at reducing the incidence of Clostridium difficile infection (CDI).
- Conditions
- Clostridium Difficile Infection, VRE Infection, Nosocomial Infection, MRGN Bacteria
- Trial name
- ABSOLUTE (NCT03250104)
- Testing
- Infection Control, Antibiotic Stewardship
- Where
- Germany
- Volunteers
- 80,000 people
- Sponsor
- University Hospital of Cologne
Enterococcal Bacteremia
VENOUS: A Translational Study of Enterococcal Bacteremia
The purpose of this study is to assemble a multicenter prospective cohort of patients with enterococcal bloodstream infections (BSIs) to provide data on outcomes of patients with enterococcal BSIs for sample size calculations for…
- Trial name
- NCT04410276
- Where
- 12 sites in United States, Argentina and 3 more
- Volunteers
- 1,000 people
- Sponsor
- The University of Texas Health Science Center, Houston
Carbapenem-Resistant Enterobacteriaceae Infection, Vancomycin-Resistant Enterococcal Infection
The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms
The purpose of this study is to assess the effect of fecal microbiota transplantation for the decolonization of carbapenem-resistant Enterobacteriaceae or vancomycin-resistant Enterococci in the gut.
- Trial name
- NCT04583098
- Testing
- fecal microbiota transplantation
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Antimicrobial Drug Resistance, Antibiotic Resistant Infection
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
The goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization period and evaluate if some populations of specific bacteria increase or…
- Conditions
- Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection
- Trial name
- DYNAMITE (NCT06258551)
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Clostridium Difficile Infection
Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients
Vancomycin-resistant Enterococcus (VRE) and carbapenem-resistant Enterobacteriaceae (CRE) are multi-drug resistant organisms (MDROs) associated with healthcare settings and are a high priority for containment in public health.
- Trial name
- NCT03643887
- Testing
- FMT Capsule DE
- Sponsor
- University of Wisconsin, Madison